As part of our tradition of innovation, Pharmaseed’s 20 years of expertise encompass a wide range of unique 𝘪𝘯-𝘷𝘪𝘵𝘳𝘰 𝘢𝘯𝘥 𝘪𝘯-𝘷𝘪𝘷𝘰 models, advanced research capabilities, and clinical services.
🔹 𝐎𝐮𝐫 𝐯𝐚𝐥𝐮𝐞 𝐩𝐫𝐨𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧:
• GLP conditions
• Accelerated study tracks, under 2 months to in-vivo study initiation
• +50% PhD level personnel
• A 20-year proven track record of successful regulatory submissions
• +85% returning clients
• Experience working with the startup, big pharma, medical device, nutraceutical, and cannabis industries
🔹 𝐖𝐢𝐝𝐞 𝐫𝐚𝐧𝐠𝐞 𝐨𝐟 𝒊𝒏-𝒗𝒊𝒕𝒓𝒐 𝐚𝐧𝐝 𝒊𝒏-𝒗𝒊𝒗𝒐 𝐦𝐨𝐝𝐞𝐥𝐬: cardiovascular disease, oncology, immunology, immuno-oncology (hot & cold tumors), inflammation, neurology, metabolic disorders, microbiome, infectious disease, and ophthalmology, aging and longevity.
🔹𝐄𝐱𝐩𝐞𝐫𝐭𝐢𝐬𝐞 𝐢𝐧 𝐚𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬: gene & cell therapy, gene editing, stem cells, 3D cultures, engineered cells (NK, CAR-NK CAR-T, TIL) and immune checkpoint inhibitors.
🔹 𝐁𝐋2 𝐬𝐚𝐟𝐞𝐭𝐲 𝐮𝐧𝐢𝐭: bacteria – such as MRSA, bacteriophages, viruses (oncolytic viruses, influenza, pneumonia, corona, etc.), and microbiome manipulations
🔹𝐀𝐧𝐢𝐦𝐚𝐥𝐬: rodents – mice, rats, rabbits; large animals – swine, sheep; unique models – 𝘤. 𝘦𝘭𝘦𝘨𝘢𝘯𝘴, 𝘥𝘳𝘰𝘴𝘰𝘱𝘩𝘪𝘭𝘢 𝘮𝘦𝘭𝘢𝘯𝘰𝘨𝘢𝘴𝘵𝘦𝘳, 𝘥𝘢𝘯𝘪𝘰 𝘳𝘦𝘳𝘪𝘰 / zebrafish.
🔹𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥 𝐝𝐞𝐬𝐢𝐠𝐧 𝐚𝐧𝐝 𝐞𝐱𝐞𝐜𝐮𝐭𝐢𝐨𝐧
🔹 𝐅𝐨𝐫 𝐦𝐨𝐫𝐞 𝐝𝐞𝐭𝐚𝐢𝐥𝐬 𝐠𝐨 𝐭𝐨 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞: 𝐡𝐭𝐭𝐩𝐬://𝐰𝐰𝐰.𝐩𝐡𝐚𝐫𝐦𝐚𝐬𝐞𝐞𝐝𝐥𝐭𝐝.𝐜𝐨𝐦/